Patricia Comella-del-Barrio

Dr. Patricia Comella-del-Barrio

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PCPatricia Comella-del-Barrio
Patricia Comella-del-Barrio
JBJohn Samson Bimba
John Samson Bimba
RARamota Adelakun
Ramota Adelakun
KKKonstantina Kontogianni
Konstantina Kontogianni
BMBarbara Molina-Moya
Barbara Molina-Moya
JDJose Dominguez
Jose Dominguez
There is a need for diagnostics for tuberculosis (TB) that are easy to use, able to screen non-sputum samples, and able to provide rapid results for the management of both immunocompromised and immunocompetent individuals. The Fujifilm SILVAMP TB LAM (FujiLAM) assay, a new non-sputum based point of need test for the diagnosis of TB, could potentially address most of these needs. We evaluated the performance of FujiLAM in HIV positive and HIV negative patients with presumptive TB attending three district hospitals in Nigeria. Consecutive patients were asked to provide urine samples on the spot, which were tested with FujiLAM. The results were compared against a positive culture and/or Xpert MTB/RIF as the reference standard. Forty-five patients had bacteriologically confirmed TB, and 159 had negative culture and Xpert MTB/RIF (no TB). The FujiLAM test was positive in 23 (sensitivity 65.7%, 95% CI = 48–80) HIV negative and seven (70%, 95% CI = 35–92) HIV positive patients with bacteriological confirmation of TB. FujiLAM was negative in 97 (specificity 99.0%, 95% CI = 94–100) HIV negative and 56 (93.3%, 95% CI = 83–98) HIV positive patients without TB. The FujiLAM test has good diagnostic accuracy for considering its application in both HIV positive and HIV negative patients with TB.

28 April 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PCPatricia Comella-del-Barrio
Patricia Comella-del-Barrio
BMBarbara Molina-Moya
Barbara Molina-Moya
JGJacqueline Gautier
Jacqueline Gautier
RHRaquel Villar Hernandez
Raquel Villar Hernandez
MDMariette Jean Coute Doresca
Mariette Jean Coute Doresca
JDJose Dominguez
Jose Dominguez
Current diagnostics for tuberculosis (TB) only manage to confirm a small proportion of children with TB and require respiratory samples, which are difficult to obtain. There is a need for non-invasive biomarker-based tests as an alternative to sputum testing. Fujifilm SILVAMP TB lipoarabinomannan (FujiLAM), a lateral-flow test to detect lipoarabinomannan in urine, is a novel non-sputum-based point-of-care diagnostic reported to have increased sensitivity for the diagnosis of TB among human immunodeficiency virus (HIV)-infected adults. We evaluate the performance of FujiLAM in children with presumptive TB. Fifty-nine children attending a paediatric hospital in Haiti with compatible signs and symptoms of TB were examined using Xpert MTB/RIF, smear microscopy and X-rays, and classified according to the certainty of diagnosis into bacteriologically confirmed TB (n = 5), unconfirmed TB (bacteriologically negative, n = 50) and unlikely TB (n = 4). Healthy children (n = 20) were enrolled as controls. FujiLAM sensitivity and specificity were 60% and 95% among children with confirmed TB. FujiLAM’s high specificity and its characteristics as a point-of-care indicate the test has a good potential for the diagnosis of TB in children.

Verified
Journal Article
Open access
PDF file
NANeus Altet
Neus Altet
ILIrene Latorre
Irene Latorre
MJMaría Ángeles Jiménez-Fuentes
María Ángeles Jiménez-Fuentes
ASAntoni Soriano-Arandes
Antoni Soriano-Arandes
RHRaquel Villar Hernandez
Raquel Villar Hernandez
OGon behalf of PII Smoking SEPAR Working Group
on behalf of PII Smoking SEPAR Working Group
Little is known about whether second-hand smoke (SHS) exposure affects tuberculosis (TB). Here, we investigate the association of cigarette smoke exposure with active TB and latent TB infection (LTBI) in children, analyzing Interferon-Gamma Release Assays’ (IGRAs) performance and cytokine immune responses. A total of 616 children from contact-tracing studies were included and classified regarding their smoking habits [unexposed, SHS, or smokers]. Risk factors for positive IGRAs, LTBI, and active TB were defined. GM-CSF, IFN-γ, IL-2, IL-5, IL-10, IL-13, IL-22, IL-17, TNF-α, IL-1RA and IP-10 cytokines were detected in a subgroup of patients. Being SHS exposed was associated with a positive IGRA [aOR (95% CI): 8.7 (5.9–12.8)] and was a main factor related with LTBI [aOR (95% CI): 7.57 (4.79–11.94)] and active TB [aOR (95% CI): 3.40 (1.45–7.98)]. Moreover, IGRAs’ sensitivity was reduced in active TB patients exposed to tobacco. IL-22, GM-CSF, IL-5, TNF-α, IP-10, and IL-13 were less secreted in LTBI children exposed to SHS. In conclusion, SHS is associated with LTBI and active TB in children. In addition, false-negative IGRAs obtained on active TB patients exposed to SHS, together with the decrease of specific cytokines released, suggest that tobacco may alter the immune response.

23 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NTNadiia Tytarenko
Nadiia Tytarenko
JBJohn Samson Bimba
John Samson Bimba
DVDídac Vulcano
Dídac Vulcano
PCPatricia Comella-del-Barrio
Patricia Comella-del-Barrio
OOOkoedoh Osazuwa
Okoedoh Osazuwa
JDJose Dominguez
Jose Dominguez
Background: Tuberculosis (TB) remains a leading cause of death worldwide, with major diagnostic challenges in low-resource settings. Urine-based lipoarabinomannan (LAM) assays provide a non-invasive option, particularly for people living with HIV who may struggle to produce sputum. Fujifilm has developed a second-generation SILVAMP TB LAM assay (FujiLAM v.2) to improve diagnostic performance. This study aimed to evaluate the diagnostic accuracy of FujiLAM v.2 among Nigerian adults with presumptive TB and directly compare it with the first-generation assay (FujiLAM v.1) using the same set of urine samples. Methods: We conducted a retrospective analysis among Nigerian adults with presumptive TB (n = 178). Stored urine samples collected in Abuja were retested with FujiLAM v.2 and compared with results previously obtained using FujiLAM v.1 on the same specimens. Xpert MTB/RIF and culture served as the reference standard. Sensitivity, specificity, agreement with the reference standard (Cohen’s Kappa), and differences (McNemar’s test) were assessed. Results: FujiLAM v.2 demonstrated sensitivity of 58.3% and specificity of 97.3%, comparable to FujiLAM v.1 (58.3% and 98.0%, respectively). No significant differences were found between test versions across TB or HIV subgroups (p > 0.05). Overall agreement between assays was 97.1% (κ = 0.80). Conclusions: FujiLAM v.2 showed diagnostic performance consistent with the first-generation assay, with similar sensitivity and specificity to the earlier version. These findings support its potential as a rapid, non-sputum-based diagnostic tool to complement TB testing in resource-limited settings. Further studies are needed to assess its implementation within TB diagnostic algorithms, including studies with multiple production lots.

28 September 2019 in European Respiratory Journal
Verified
Conference Paper
Closed access
PCPatricia Comella-del-Barrio
Patricia Comella-del-Barrio
Jose L. Izquierdo-GarcíaJose L. Izquierdo-García
Jose L. Izquierdo-García
RCRamón Campos-Olivas
Ramón Campos-Olivas
CSClara M Santiveri
Clara M Santiveri
JRJesús Ruiz-Cabello
Jesús Ruiz-Cabello
JDJosé Domínguez
José Domínguez
Children’s paucibacillary tuberculosis (TB) and their difficulty to expectorate leads to low diagnostic sensitivity. Most TB in children are diagnosed by clinical scoring systems limited by the TB clinical presentation. Pediatric TB diagnosis research should be focused on new biomarkers from non-invasive and non-sputum-based samples. By metabolomics we can obtain a “fingerprint” of the metabolites presents in a biological sample, allowing the study of sets of metabolites affected by host-pathogen interactions and the identification of diagnostic markers. This study aims to identify urine metabolite biomarkers with pediatric TB diagnostic potential. The urine spectra from High-resolution 1H Nuclear Magnetic Resonance (NMR) spectroscopy were obtained in a cross-sectional study of 73 children (0-14 years) screened for suspected TB in a pediatric hospital of Haiti. Enrolled children had a positive Tuberculin Skin Test and were classified as follows: 23 TB, 27 probable TB, 13 unlikely TB, and 10 latent TB infection (LTBI). Among all NMR tested samples, an algorithm was developed with 33 spectra from core groups (23 TB, 10 LTBI). We identified eight metabolites with significant changes between groups and when comparing TB and LTBI, we achieved a specificity and sensitivity of 95.49% and 89.90%, respectively. Moreover, when including probable TB and unlikely TB, we classified 92.65% and 53.85%, respectively as TB. We suggest a combination of metabolites that discriminate TB from LTBI, improving the diagnostic accuracy. This urine-based metabolomic algorithm may improve the pediatric TB diagnosis identifying those children with unconfirmed TB diagnostic and therefore, reducing the undiagnosed pediatric TB.